In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity
LEGENDARY ACQUITY PERFORMANCE.AT EVERY LEVEL FOR EVERY LAB.
In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity.
Today, Waters meets the ever-growing demand for higher levels of resolution and sensitivity with an ever-growing family of ACQUITY® Systems. That means for virtually any application, in every analytical lab, all over the world, there’s an ACQUITY System that’s right for you. To find the one that’s right for your lab, visit waters.com/ACQUITY.
Corporate Headquarters
Waters Corporation
34 Maple Street
Milford, MA 01757
T: 508-478-2000 or 1-800-252-4752
F: 508-872-1990
European Headquarters
Waters S.A.S.
BP 608
78056 Saint-Quentin
En Yvelines Cedex, France
T: 33 1 30 48 72 00
F: 33 1 30 48 72 01
www.waters.com
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.